Side-by-side · Research reference

CartalaxvsHGH Fragment 176-191

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED10/32 cited

BAnimal-StrongHUMAN-REVIEWED28/59 cited

Cartalax

Bioregulator Peptide · Khavinson School

CartilagePrimary tissuePovorozniuk 2007

MSC → ChondrocyteDifferentiation axisLinkova 2023

BMD ↑Bone density effectPovorozniuk 2007

SQ · Protocol Unspecified

HGH Fragment 176-191

GH Fragment · Pre-Clinical

50%Weight gain reductionNg 2000

~26 minHalf-life (est.)

No IGF-1 ↑GH axis impact

SQ · IP (animal) · Oral (tested)

01Mechanism of Action

Parameter

Cartalax

HGH Fragment 176-191

Primary target

Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023

Beta-3 adrenergic receptors on adipocytesHeffernan 2001

Pathway

Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023

Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001

Downstream effect

Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023 Povorozniuk 2007

Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation

Feedback intact?

—

N/A — does not interact with GH/IGF-1 axis

Origin

Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007

Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015

Antibody development

—

Not reported in available studies

02Dosage Protocols

Parameter

Cartalax

HGH Fragment 176-191

Animal model dose

Unspecified (cartilaginous tissue extract protocol)

Rat study; extract preparation details not indexed in available abstracts.

—

Human dosing

Not established in PubMed-indexed literature

Russian-tradition protocols exist but lack peer-reviewed Western validation.

—

Evidence basis

Animal mechanistic studies only

Animal studies only

Animal dose (oral)

—

500 mcg/kg body weightNg 2000

Obese Zucker rats, 19 days.

Animal dose (IP)

—

Not specified (14-day chronic administration)Heffernan 2001

Obese mice, daily IP injection.

Human equivalent dose

—

Not established — no published human RCTs

Frequency

—

Once daily (animal models)

Duration tested

—

14–19 daysHeffernan 2001 Ng 2000

Detection window

—

50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015

WADA-banned; anti-doping testing available.

Oral bioavailability

—

Demonstrated efficacy in animal oral administrationNg 2000

Potential for oral therapeutic development.

03Metabolic / Fat Loss Evidence

Parameter

Cartalax

HGH Fragment 176-191

Fat loss evidence

None — primary target is cartilage and bone tissue, not adipose

—

Primary fat target

—

Adipose tissue (general) — beta-3 AR mediated lipolysisHeffernan 2001

Weight gain reduction

—

50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000

Obese Zucker rats, 19 days oral administration.

Body fat reduction

—

Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001

Lipolytic activity

—

Increased adipose tissue lipolytic activityNg 2000

Direct measurement in treated animals.

Beta-3 AR expression

—

Upregulated β3-AR mRNA in obese mice to lean-comparable levelsHeffernan 2001

Insulin sensitivity

—

No adverse effect — euglycemic clamp confirmedNg 2000

Contrasts with intact hGH diabetogenic effects.

IGF-1 impact

—

No elevation — fragment does not activate GH/IGF-1 axis

Beta-3 AR dependency

—

Effect abolished in β3-AR knockout miceHeffernan 2001

Confirms β3-AR as primary mechanism.

Route of administration

—

Efficacy demonstrated via oral and IP routesNg 2000 Heffernan 2001

Human evidence

—

None published — pre-clinical only

04Side Effects & Safety

Parameter

Cartalax

HGH Fragment 176-191

Documented adverse effects

None reported in indexed animal studies

—

Human safety data

Not available in PubMed-indexed literature

Not available — no published human trials

Insulin sensitivity

—

No adverse effects observed in euglycemic clamp (animal)Ng 2000

GH/IGF-1 axis

—

No activation — avoids diabetogenic effects of full GHNg 2000

WADA status

—

Banned as performance-enhancing drugCox 2015

Metabolic profile

—

Six metabolites identified; CRSVEGSCG most stableCox 2015

Detection window implications for doping control.

Absolute Contraindications

Cartalax

·Unknown due to lack of human clinical trial data

HGH Fragment 176-191

·Competitive athletes (WADA-banned)Cox 2015

Relative Contraindications

Cartalax

·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)

HGH Fragment 176-191

·Absence of human safety data — experimental use only

05Administration Protocol

Parameter

Cartalax

HGH Fragment 176-191

1. Route

Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.

Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.

2. Frequency

Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.

Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.

3. Storage

Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.

Animal protocols: 14–19 days. Human duration not established — no published trials.

4. Storage

—

Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.

5. Detection

—

Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015